A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS

Immunogenicity, Vaccine Clinical Trial

Official title:
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHILDREN AGED 5 MONTHS TO ≤60 MONTHS AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS

Status Completed

Clinical Trial Summary

This is a PAC study after PCV13 launch in China. Based on recommendation from China Agency, Pfizer was required to conduct a descriptive immunogenicity study to measure the antibody levels at the time of disease onset.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05372575
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	N/A
Start date	August 15, 2019
Completion date	December 14, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05298800` - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23	Phase 4
Recruiting	`NCT04725669` - Seroprevalence of Pertussis Among Children and Adolescents in Croatia	N/A
Completed	`NCT04756817` - Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece
Recruiting	`NCT03405805` - Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules	N/A
Completed	`NCT05104359` - COVID-19 Quantitative Antibody Titers & Booster Vaccinations